These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 11810552

  • 1. Mechanism of quinolone resistance in Staphylococcus aureus.
    Tanaka M, Wang T, Onodera Y, Uchida Y, Sato K.
    J Infect Chemother; 2000 Sep; 6(3):131-9. PubMed ID: 11810552
    [Abstract] [Full Text] [Related]

  • 2. Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains.
    Wang T, Tanaka M, Sato K.
    Antimicrob Agents Chemother; 1998 Feb; 42(2):236-40. PubMed ID: 9527766
    [Abstract] [Full Text] [Related]

  • 3. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [Abstract] [Full Text] [Related]

  • 4. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
    Ng EY, Trucksis M, Hooper DC.
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
    [Abstract] [Full Text] [Related]

  • 5. [A study on the resistance of Staphylococcus aureus and the mechanisms of its resistance to fluoroquinolone].
    Lei Y, Gui X, Feng G.
    Zhonghua Nei Ke Za Zhi; 2001 Mar; 40(3):176-9. PubMed ID: 11798575
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
    Schmitz FJ, Fluit AC, Brisse S, Verhoef J, Köhrer K, Milatovic D.
    FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
    [Abstract] [Full Text] [Related]

  • 9. Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro.
    Ruiz J, Sierra JM, De Anta MT, Vila J.
    Int J Antimicrob Agents; 2001 Aug; 18(2):107-12. PubMed ID: 11516932
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
    Fukuda H, Hori S, Hiramatsu K.
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1917-22. PubMed ID: 9687384
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Evaluation of a high-density oligonucleotide array for characterization of grlA, grlB, gyrA and gyrB mutations in fluoroquinolone resistant Staphylococcus aureus isolates.
    Couzinet S, Yugueros J, Barras C, Visomblin N, Francois P, Lacroix B, Vernet G, Lew D, Troesch A, Schrenzel J, Jay C.
    J Microbiol Methods; 2005 Feb; 60(2):275-9. PubMed ID: 15590102
    [Abstract] [Full Text] [Related]

  • 15. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.
    Ferrero L, Cameron B, Crouzet J.
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1554-8. PubMed ID: 7492103
    [Abstract] [Full Text] [Related]

  • 16. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
    Yun HJ, Min YH, Jo YW, Shim MJ, Choi EC.
    Int J Antimicrob Agents; 2005 Apr; 25(4):334-7. PubMed ID: 15784314
    [Abstract] [Full Text] [Related]

  • 17. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
    Jones ME, Critchley IA, Karlowsky JA, Blosser-Middleton RS, Schmitz FJ, Thornsberry C, Sahm DF.
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
    Cheng J, Thanassi JA, Thoma CL, Bradbury BJ, Deshpande M, Pucci MJ.
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
    [Abstract] [Full Text] [Related]

  • 20. Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.
    Takahata M, Yonezawa M, Kurose S, Futakuchi N, Matsubara N, Watanabe Y, Narita H.
    J Antimicrob Chemother; 1996 Sep; 38(3):543-6. PubMed ID: 8889728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.